Last reviewed · How we verify
spironolactone + furosemide
Spironolactone blocks aldosterone to retain potassium while furosemide inhibits sodium reabsorption to promote diuresis, together providing balanced fluid and electrolyte management.
Spironolactone blocks aldosterone to retain potassium while furosemide inhibits sodium reabsorption to promote diuresis, together providing balanced fluid and electrolyte management. Used for Edema and fluid overload in heart failure, Edema in cirrhosis and renal disease, Hypertension with hypokalemia risk.
At a glance
| Generic name | spironolactone + furosemide |
|---|---|
| Sponsor | Tottori University Hospital |
| Drug class | Diuretic combination (potassium-sparing diuretic + loop diuretic) |
| Target | Aldosterone receptor (spironolactone); Na-K-2Cl cotransporter (furosemide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Spironolactone is a potassium-sparing diuretic that antagonizes aldosterone in the collecting duct, reducing sodium reabsorption and potassium excretion. Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter, producing potent diuresis but causing potassium loss. Combined, they provide synergistic diuretic effect while the potassium-sparing action of spironolactone counterbalances furosemide-induced hypokalemia.
Approved indications
- Edema and fluid overload in heart failure
- Edema in cirrhosis and renal disease
- Hypertension with hypokalemia risk
Common side effects
- Hyperkalemia
- Hyponatremia
- Dehydration
- Hypotension
- Gynecomastia (spironolactone)
- Ototoxicity (furosemide)
Key clinical trials
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. (NA)
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients (NA)
- To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation. (NA)
- Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (PHASE1, PHASE2)
- Risk Stratification of Heart Failure in Cardiomyopathies. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- spironolactone + furosemide CI brief — competitive landscape report
- spironolactone + furosemide updates RSS · CI watch RSS
- Tottori University Hospital portfolio CI